Journals / Düzce Tıp Fakültesi Dergisi / 2022 / Cilt: 24 - Sayı: Special Issue

Optimizing Female Infertility in Premature Ovarian Insufficiency

Erken Yumurtalık Yetersizliğinde Kadın İnfertilitesinin Optimizasyonu

Pages
63–67
Publication Date
2022-10-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the present review, the current pathophysiology and treatment options of premature ovarian failure were discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Premature ovarian failure is a complex pathology with numerous etiologies and multiple system sequelae resulting for early deprivation of ovarian sex hormones.
📊
Key Findings & Data:In fact, fertility, which begins to decrease before menstrual irregularity, turns into infertility with a rapid decline in the number of follicles in the following period.
💡
Conclusion & Impact:In the present review, the current pathophysiology and treatment options of premature ovarian failure were discussed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Erken yumurtalık yetersizliği · infertilite · tanı

Abstract

Premature ovarian failure is a complex pathology with numerous etiologies and multiple system sequelae resulting for early deprivation of ovarian sex hormones. In the studies to determine the etiology, it is seen that many patients are in the unexplained group. On the other hand, genetic predisposition and autoimmune cause of premature ovarian insufficiency (POI) are the most common known etiologic causes. Early diagnosis and energetic treatment are important in order to prevent symptoms related to estrogen deficiency. Initiating hormone replacement therapy as soon as possible will prevent menopausal symptoms and reduce long-term complications in women. Another important problem in these patients is infertility, which occurs due to ovarian failure. In fact, fertility, which begins to decrease before menstrual irregularity, turns into infertility with a rapid decline in the number of follicles in the following period. Here, the detection of patients at risk and appropriately timed fertility preservation treatments (such as freezing of oocyte, embryo, or ovarian tissue) or assisted reproductive techniques can be offered. Besides this, studies like stem cell therapy, platelet-rich plasma (PRP), and in vitro activation of ovarian tissue in patients with POI are recent and still investigational but may be promising in the future. In the present review, the current pathophysiology and treatment options of premature ovarian failure were discussed.

Özet

Erken yumurtalık yetmezliği, az bilinen etiyolojisi ile neden olduğu yumurtalık hormonlarının azalmasıyla saptanan, kadınlarda birçok sistemi etkileyen patolojilere yol açar. Etiyolojisini belirlemeye yönelik çalışmalarda pek çok hastanın açıklanamayan grupta olduğu görülmektedir. Diğer yandan genetik yatkınlık ve otoimmün nedenli erken yumurtalık yetersizliği (premature ovarian insufficiency, POI) bilinen en sık etiyolojik nedenlerdir. Temelde östrojen eksikliği ile ilgili semptomların önlenmesi amacı ile erken tanı ve tedavi önemlidir. Hormon replasman tedavisinin bir an önce başlanması, kadınlarda menopozal semptomların önlenmesini ve uzun dönemli komplikasyonların azalmasını sağlayacaktır. Bu hastalarda diğer önemli sorun ise over yetmezliği ile ortaya çıkan infertilitedir. Aslında adet düzensizliği ortaya çıkmadan önce azalmaya başlayan fertilite, ilerleyen dönemde folikül sayısının daha hızlı azalması ile ciddi bir infertilite sorunu haline gelmektedir. Burada özellikle risk altındaki hastaların tespiti ile uygun zamanda fertilite koruyucu tedaviler (oosit, embryo veya over dokusunun dondurulması gibi) ve yardımla üreme teknikleri önerilebilir. Bununla birlikte, infertilite yakınması olan POI tanısı alan hastalarda; kök hücre tedavisi, trombositten zengin plazma (platelet-rich plasma, PRP) ve over dokusuna in vitro aktivasyon gibi uygulamalar yeni ve deneysel aşamada olsa da gelecekte umut verici olabilir. Sunulan bu derlemede erken yumurtalık yetmezliğinin güncel patofizyolojisi ve tedavi seçenekleri tartışılmıştır.

🔖

Cite This Article

AYTAÇ, P. Ç. (2022). Optimizing Female Infertility in Premature Ovarian Insufficiency. Düzce Tıp Fakültesi Dergisi, Cilt: 24 - Sayı: Special Issue, 63–67. https://ajindex.com/articles/656122

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926-37.
  2. Golezar S, Ramezani Tehrani F, Khazaei S, Ebadi A, Keshavarz Z. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric. 2019;22(4):403-11.
  3. Hubayter ZR, Popat V, Vanderhoof VH, Ndubizu O, Johnson D, Mao E, et al. A prospective evaluation of antral follicle function in women with 46,XX spontaneous primary ovarian insufficiency. Fertil Steril. 2010;94(5):1769-74. van Kasteren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update. 1999;5(5):483-92.
  4. Maclaran K, Panay N. Current concepts in premature ovarian insufficiency. Womens Health (Lond). 2015;11(2):169-82.
  5. Luborsky JL, Meyer P, Sowers MF, Gold EB, Santoro N. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod. 2003;18(1):199-206.
  6. Chang SH, Kim CS, Lee KS, Kim H, Yim SV, Lim YJ, et al. Premenopausal factors influencing premature ovarian failure and early menopause. Maturitas. 2007;58(1):19-30.
  7. Turkyilmaz A, Alavanda C, Ates EA, Geckinli BB, Polat H, Gokcu M, et al. Whole-exome sequencing reveals new potential genes and variants in patients with premature ovarian insufficiency. J Assist Reprod Genet. 2022;39(3):695-710.
  8. Lambrinoudaki I, Paschou SA, Lumsden MA, Faubion S, Makrakis E, Kalantaridou S, et al. Premature ovarian insufficiency: A toolkit for the primary care physician. Maturitas. 2021;147:53-63.
  9. Tartagni M, Cicinelli E, De Pergola G, De Salvia MA, Lavopa C, Loverro G. Effects of pretreatment with estrogens on ovarian stimulation with gonadotropins in women with premature ovarian failure: a randomized, placebo-controlled trial. Fertil Steril. 2007;87(4):858-61.
  10. Badawy A, Goda H, Ragab A. Induction of ovulation in idiopathic premature ovarian failure: a randomized double-blind trial. Reprod Biomed Online. 2007;15(2):215-9.
  11. Check JH, Nowroozi K, Chase JS, Nazari A, Shapse D, Vaze M. Ovulation induction and pregnancies in 100 consecutive women with hypergonadotropic amenorrhea. Fertil Steril. 1990;53(5):811-6.
  12. Ishizuka B, Furuya M, Kimura M, Kamioka E, Kawamura K. Live birth rate in patients with premature ovarian insufficiency during long-term follow-up under hormone replacement with or without ovarian stimulation. Front Endo